PMID- 36580702
OWN - NLM
STAT- MEDLINE
DCOM- 20230227
LR  - 20231002
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 17
IP  - 1
DP  - 2023 Jan
TI  - Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 
      diabetes a meta-analysis.
PG  - 102697
LID - S1871-4021(22)00314-9 [pii]
LID - 10.1016/j.dsx.2022.102697 [doi]
AB  - BACKGROUND AND AIMS: No meta-analysis has analysed the safety and efficacy of 
      lobeglitazone in type-2 diabetes (T2DM). We undertook this meta-analysis to 
      address this knowledge-gap. METHODS: Electronic databases were searched for RCTs 
      involving type-2 diabetes patients receiving lobeglitazone in intervention arm, 
      and placebo/active comparator in control arm. Primary outcome was to evaluate 
      changes in HbA1c. Secondary outcomes were to evaluate alterations in glucose, 
      lipids and adverse events. RESULTS: From initially screened 65 articles, data 
      from 4 RCTs (828 patients) which fulfilled all criteria was analysed. Over 24 
      weeks, when compared to sitagliptin 100 mg/d and half maximal pioglitazone dose 
      (15 mg/d), lobeglitazone 0.5 mg/day had comparable impact on HbA1c [MD 0.03% 
      (95%CI: 0.11-0.17); P = 0.65; I(2) = 0%], fasting glucose [MD 1.47 mg/dl (95%CI: 
      4.66-7.60); P = 0.64; I(2) = 0%], triglycerides [MD-9.96 mg/dl (95%CI: 
      43.55-23.62); P = 0.56; I(2) = 81%], LDL-cholesterol [MD0.74 mg/dl (95%CI: 
      4.60-6.09); P = 0.79; I(2) = 0%] and HDL-cholesterol [MD1.55 mg/dl (95%CI: 
      3.72-6.82); P = 0.56]. Occurrence of treatment-emergent adverse events (AEs) [RR 
      1.07 (95% CI:0.78-1.47); P = 0.67; I(2) = 0%] and severe AEs [RR 1.05(95%CI: 
      0.42-2.65); P = 0.91; I(2) = 0%] were similar. Edema and weight gain were 
      significantly higher with lobeglitazone compared to controls [RR 2.58 (95%CI: 
      1.08-6.17); P = 0.03; I(2) = 0%]. Lobeglitazone 0.5 mg/d compared to half-maximal 
      pioglitazone (15 mg/d), had similar edema and weight gain [RR 1.65 95% CI: 
      0.78-1.47)]. BMD percent changes at neck of femur was comparable in both groups 
      [MD 0.07% (95%CI: 0.19-0.33); P = 0.60; I(2) = 91%]. Low dose lobeglitazone 
      (0.25 mg/d) was inferior to high dose lobeglitazone (0.5 mg/d) with regards to 
      glycaemic efficacy with advantage of lower weight gain and edema. CONCLUSION: The 
      current evidence makes lobeglitazone unlikely to replace pioglitazone as the 
      preferred thiazolidinedione in T2DM.
CI  - Copyright (c) 2022 Research Trust of DiabetesIndia (DiabetesIndia) and National 
      Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. 
      All rights reserved.
FAU - Dutta, Deep
AU  - Dutta D
AD  - Department of Endocrinology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, 
      India. Electronic address: deepdutta2000@yahoo.com.
FAU - Bhattacharya, Saptarshi
AU  - Bhattacharya S
AD  - Department of Endocrinology, Apollo Hospitals, New Delhi, India. Electronic 
      address: saptarshi515@gmail.com.
FAU - Kumar, Manoj
AU  - Kumar M
AD  - Department of Endocrinology, CEDAR Superspeciality Healthcare, Zirakpur, Punjab, 
      India. Electronic address: manojkattu@gmail.com.
FAU - Datta, Priyankar K
AU  - Datta PK
AD  - Department of Anaesthesiology, Critical Care and Pain Medicine, All India 
      Institute of Medical Sciences, New Delhi, India. Electronic address: 
      priyankar.k.datta@gmail.com.
FAU - Mohindra, Ritin
AU  - Mohindra R
AD  - Department of Medicine, Post-graduate Institute of Medical Education and 
      Research, Chandigarh, India. Electronic address: ritin.mohindra@gmail.com.
FAU - Sharma, Meha
AU  - Sharma M
AD  - Department of Rheumatology, CEDAR Superspeciality Healthcare, Dwarka, New Delhi, 
      India. Electronic address: docmsharma@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221223
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
RN  - MY89F08K5D (lobeglitazone)
RN  - 0 (Hypoglycemic Agents)
RN  - X4OV71U42S (Pioglitazone)
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Blood Glucose)
RN  - 0 (Thiazolidinediones)
RN  - AA68LXK93C (2,4-thiazolidinedione)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
CIN - Diabetes Metab Syndr. 2023 Aug;17(8):102727. PMID: 36934031
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Pioglitazone
MH  - Glycated Hemoglobin
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Thiazolidinediones/adverse effects
MH  - Weight Gain
MH  - Cholesterol
OTO - NOTNLM
OT  - Glycaemic variability
OT  - Lobeglitazone
OT  - Meta-analysis
OT  - Safety
OT  - Type-2 diabetes
COIS- Declaration of competing interest None.
EDAT- 2022/12/30 06:00
MHDA- 2023/03/03 06:00
CRDT- 2022/12/29 18:04
PHST- 2022/10/10 00:00 [received]
PHST- 2022/12/15 00:00 [revised]
PHST- 2022/12/17 00:00 [accepted]
PHST- 2022/12/30 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2022/12/29 18:04 [entrez]
AID - S1871-4021(22)00314-9 [pii]
AID - 10.1016/j.dsx.2022.102697 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2023 Jan;17(1):102697. doi: 10.1016/j.dsx.2022.102697. Epub 
      2022 Dec 23.